RA Capital Continues Reducing Stake with $262K in Werewolf Therapeutics Share Sales
HOWL is trading near its 52-week low of $0.313 (3.1% above the low).
Summary
RA Capital Management, a major institutional investor, reported additional sales of Werewolf Therapeutics stock totaling approximately $262,673, continuing a pattern of stake reduction.
Key Events · Ownership and Investor Activity · HOWL
-
Continued Stake Reduction
RA Capital Management, L.P. and its associated funds reported open market sales of Werewolf Therapeutics common stock from June 23 to June 26, 2026.
-
Significant Sales Volume
A total of 738,565 shares were sold across multiple transactions, amounting to approximately $262,673.
-
Current Ownership
Following these transactions, RA Capital Management's beneficial ownership stands at 2,915,742 shares, representing 6.0% of the company's outstanding common stock.
-
Sales Near 52-Week Lows
The sales occurred at average prices ranging from $0.32 to $0.37 per share, while the stock is trading near its 52-week low of $0.3133.
Analysis · HOWL · Life Sciences
This filing details RA Capital Management's continued reduction of its stake in Werewolf Therapeutics through open market sales totaling approximately $262,673 over four days. These sales, occurring while the stock trades near its 52-week low, contribute to a broader pattern of institutional distribution observed in recent months. While RA Capital remains a significant shareholder with a 6.0% stake, the consistent selling by a major investor can exert downward pressure on the stock and signals a lack of conviction at current price levels.
At the time of this filing, HOWL was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $0.31 to $2.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.